Across the trials, different combinations of SGLT2 inhibitors, DPP-4 inhibitors, metformin, and insulin were administered to evaluate their impact on glycemic control, cardiovascular and renal outcomes, weight changes, and hypoglycemia risks. This evidence concerns the gene INS and Hypoglycemia.